The U.S. Department of Defense wrote a $749,000 check in March 2022. The recipient was not a missile maker or a satellite firm, but a Boulder-based startup with nine employees and a patent for hiding secrets inside DNA [PitchBook, March 2022]. GeneInfoSec’s premise is simple, if audacious: the most sensitive data in the world is genetic, and the most secure place to protect it is at the molecular level, before it ever touches a vulnerable computer.
Founded in 2016, the company sells a dual offering. Its core technology is a molecular cryptography platform that synthesizes cryptographic tags attached directly to DNA samples. Its consulting arm provides bioinformatics security audits and staff training [Perplexity Sonar Pro Brief, 2026]. The customer base, so far, is defined by that first government grant. The company is betting that national security labs, biotech research facilities, and sequencing centers will pay for a new kind of assurance,one that starts in the test tube.
A Cryptographic Wedge in the Test Tube
Conventional data security begins after digitization, protecting files on networks and in databases. GeneInfoSec argues the point of failure is earlier. Its platform is designed to embed security directly into the physical genetic material. Short, synthesized tags containing cryptographic information are attached to DNA molecules. The data is obfuscated at the sample level, creating what the company calls “anonymous data sharing” capabilities that persist even if downstream lab systems are compromised [SBIR.gov, 2021].
This molecular-first approach is the company’s primary wedge. It is a bet on specialization over generality. While traditional cybersecurity vendors secure servers, GeneInfoSec aims to secure the sample. The company has also developed an interim “pseudomolecular encryption” method applied at the software level post-sequencing, serving as a bridge while the full wet-lab process matures [GenomeWeb, August 2021].
The Team Behind the Patent
The founding team blends deep technical research with applied security expertise. CEO Sterling Sawaya holds a Ph.D. and is listed as the inventor of molecular cryptography, with multiple academic publications on the topic dating back to 2017 [BioRxiv, 2017]. Co-founder and CTO Aaron Hansen and Co-founder Garrett Schumacher, who also serves as COO, co-authored a foundational paper on genetic information insecurity with Sawaya in 2020 [Frontiers in Bioengineering and Biotechnology, 2020].
Their backgrounds suggest a focus on the intersection of theoretical biosecurity and practical implementation. Schumacher, for instance, concurrently holds a role as Product Security Director at medical device firm Velentium [hubXchange, 2026]. The team’s composition, leaning heavily on technical founders with published research, aligns with a company whose product is rooted in a patented scientific process rather than a software feature set.
| Role | Name | Key Background |
|---|---|---|
| Founder & CEO | Sterling Sawaya, Ph.D. | Inventor of molecular cryptography; author of related academic papers [BioRxiv, 2017]. |
| Co-Founder & CTO | Aaron Hansen | Co-author on genetic security research; former Principal Cybersecurity Expert at GeneInfoSec [LinkedIn, 2026]. |
| Co-Founder & COO | Garrett Schumacher | Co-author on genetic security research; Product Security Director at Velentium Medical [hubXchange, 2026]. |
| Key Personnel | Demetrius King | Co-Founder & Chief Operating Officer [LinkedIn, 2026]. |
Traction and the Government Path
GeneInfoSec’s disclosed financial footprint is almost entirely non-dilutive, government-backed capital. The $749,000 DoD grant in 2022 followed a $46,973 award from the U.S. Air Force in 2021 [SBIR.gov, 2021]. PitchBook notes the 2022 grant was categorized as “Generating Revenue” [PitchBook, March 2022]. This funding path is a significant traction signal and a potential moat. Winning competitive defense grants requires technical validation and aligns the company with a high-stakes, deep-pocketed initial customer: the U.S. government’s biosecurity apparatus.
The company’s public commercial traction is less visible. LinkedIn lists a team of nine, and Crunchbase estimates 1-10 employees, consistent with a firm in a protracted R&D and early commercialization phase [LinkedIn, 2026] [Crunchbase, 2026]. The consulting division, launched in 2021-2022, provides a services-based revenue stream while the core platform technology is developed and sold [GenomeWeb, August 2021].
2021 Air Force Grant | 46.973 | K USD
2022 DoD Grant | 749 | K USD
The Commercialization Hurdle
The risks for GeneInfoSec are not about technical novelty, but market adoption and scale. The company operates in a niche defined by two high barriers: the need for wet-lab integration and a customer base that must value genetic data security highly enough to overhaul sample-handling protocols. The most credible pressure point is whether the market is large enough and moving fast enough to support a venture-scale business built on this specific wedge.
- Integration complexity. Adopting molecular cryptography requires changes at the physical sample preparation stage, a deeper integration than installing software. This raises the cost of sale and slows sales cycles.
- Defined market size. The immediate addressable market appears to be government biosecurity and high-security research labs. Expansion into broader healthcare or commercial biotech requires those sectors to prioritize genetic data security at a new level of rigor.
- Funding scale. To date, the company has raised less than $800,000 in disclosed grants. Scaling sales, marketing, and further R&D for a hardware-software hybrid will likely require a substantial equity round from institutional investors.
The company’s answer is its consulting foothold and the interim software solution. These provide immediate utility and revenue while educating the market on the broader threat,and the need for their ultimate solution.
The Next Twelve Months
For a company eight years in, the next phase is about transition. The key milestones to watch are a shift from grant funding to venture capital, the signing of a first named commercial customer beyond government contracts, and the publication of a detailed case study using the molecular platform. The hiring of a Senior Software Engineer in January 2025 suggests ongoing product development [LinkedIn, 2026].
The 2022 DoD grant of $749,000 validated the concept for a demanding buyer. The question for Sawaya and his team is whether they can convert that validation into a repeatable commercial motion. Can they land a flagship biopharma or sequencing giant, and will that be enough to attract the Series A check needed to move from a promising research project to a category-defining business? The bet is that in an era of synthetic biology and personalized medicine, the most valuable data needs a new kind of lock. GeneInfoSec is building it one molecule at a time.
Sources
- [PitchBook, March 2022] GeneInfoSec 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/459703-54
- [Perplexity Sonar Pro Brief, 2026] GeneInfoSec company overview and product description
- [SBIR.gov, 2021] GeneInfoSec SBIR award details | https://www.sbir.gov/node/2064071
- [GenomeWeb, August 2021] GeneInfoSec Wants Genetic Data Security to Start at Molecular Level | https://www.genomeweb.com/informatics/geneinfosec-wants-genetic-data-security-start-molecular-level
- [BioRxiv, 2017] Cryptography for genetic material | https://www.biorxiv.org/content/early/2017/06/30/157685.1
- [Frontiers in Bioengineering and Biotechnology, 2020] Genetic Information Insecurity as State of the Art
- [LinkedIn, 2026] GeneInfoSec Inc. company page and employee profiles | https://www.linkedin.com/company/geneticinformationsecurity
- [Crunchbase, 2026] GeneInfoSec - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/geneinfosec
- [hubXchange, 2026] Garrett Schumacher profile | https://hubxchange.com/speakers/garrett-schumacher